Navigation Links
Drug Dropout in Clinical Trials Is at Unsustainable Levels, According to Thomson Reuters, CMR International
Date:6/26/2011

PHILADELPHIA and LONDON, June 26, 2011 /PRNewswire/ -- The pharmaceutical industry spent less on drug R&D last year than at any time in the last three years, according to data released today from the 2011 Pharmaceutical R&D Factbook complied by CMR International, a Thomson Reuters business.

Key highlights from the 2011 R&D Factbook include:

  • 21 new molecular entities (NMEs) were launched on the global market in 2010, a decrease from 26 in the previous year.
  • 2010 saw the lowest number of NMEs launched by Major Pharma in the past 10 years
  • The number of drugs entering Phase I and Phase II trials fell 47% and 53% respectively
  • Self-originated molecules have a 20% greater chance of reaching the market from Phase III and Submission versus in-licensed or acquired compounds
  • Patient recruitment for clinical trials has shifted towards SE Asia
  • The proportion of total sales from drugs reached an all time high of $856 billion*

The 2011 edition of the Pharmaceutical R&D Factbook shows that R&D expenditure continued to drop in 2010 to an estimated three year low of $68 billion, which is in stark contrast to the growth rate leading up to 2008. The report also highlights that drug success rates continue to show the declining trends of the past decade. There were 55 phase III drug terminations during 2008-2010, more than double the number of terminations during 2005-2007; in addition the number of drugs entering phase III clinical trials fell by 55 percent in 2010.

Faced with more than 110 drugs losing patent exclusivity in the US, including 14 "blockbusters", the world's leading pharmaceutical companies face considerable risk to their revenue streams in next three years. The strategy of in-licensing or acquiring compounds is also facing difficulty, as self-originated drugs currently have a 20% higher chanc
'/>"/>

SOURCE Thomson Reuters
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
3. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
4. Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
7. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
11. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  Next month, executives from clinical trial marketing firm ... beginning with Patient-Centered Clinical Trials 2014 , to be ... , September 4-5. Patient recruitment experts Bonnie A. ... will share insights on the benefits of employing an ... – from media to mobile apps – can be used ...
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ( ... novel mid- to late-stage cardiovascular drug candidates, today ... its first round of financing. The Series A ... Hercules Bioventures with participation from investors that included ... executive, Dr. Larry Hsu , the founder ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 A ... around the world is available from Strategic Consulting, ... companies. “ Industrial Microbiology Market Review, Fourth Edition: ... Market ” (IMMR—4) tracks and compares microbiology test ... North America, Europe and Asia, and forecasts future ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 ... is offering a promotion for Eppendorf Safe ... customers to purchase the highest quality tubes at ... are ideal for customers doing chemical, medical, pharmaceutical, ... technicians who are not regularly able to afford ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... EDMONTON, April 22 /PRNewswire-FirstCall/ - Quest PharmaTech ... announce that it will receive,generous support from ... (SDT) for oncology applications., Sonodynamic Therapy ... in,Hypocrellin-based photodynamic therapy for oncology and skin ...
... $250,000 under March ... ... BMRX), a leading developer and supplier of consumer-based,finger-activated products, today announced ... personnel of Sequiam,Corporation (OTC Bulletin Board: SQUME) through a previously announced,agreement ...
... Conn., April 22 Rib-X Pharmaceuticals, Inc.,("Rib-X" ... on the,discovery and development of novel antibiotics ... that Graham Johnson,Ph.D., Chief Research Officer and ... Cambridge Healthtech Institute,s 2nd Annual "The,Challenge of ...
Cached Biology Technology:Quest PharmaTech Receives Support from National Research Council's Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer 2bioMETRX, Inc. Initiates Integration of Personnel and Assets of Sequiam Corp. 2Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institute's 2nd Annual Challenge of Antibacterial Development Conference 2
(Date:8/29/2014)... type and number of connections in transcription factor networks ... in a study published in PLOS Computational Biology ... assortativity signature contributes to a network,s resilience against mutations. ... out-out assortativity of TFN models has a greater effect ... types of assortativity," said Dov A. Pechenick, PhD, lead ...
(Date:8/29/2014)... twist them, fold them: modern materials that are light, ... as artificial skin or electronic paper. , Making such ... but a new way of working with copper nanowires ... , Previous success in the field of ultra-lightweight ... precious gold and silver nanowires. , By turning ...
(Date:8/28/2014)... an expansion of marine protected areas is needed to ... According to investigators from the Wildlife Conservation Society and ... on saving the largest numbers of species, often at ... difficult-to-replace ecological functions. , Many vital ecological ... that also are food for millions of people. ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Copper shines as flexible conductor 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... EUGENE, Ore. -- Using new optical equipment, a ... of virtual reality, monitored both their behavior and brain ... brain operates as it moves. The new research ... Scientific Instrumentation Inc. (ASI) -- should help neuroscientists around ...
... largest celebration of science and engineering, the USA ... D.C., April 28-29, 2012. For the second year, ... hands-on experiments. At Carnegie,s booth last year, visitors ... produced by our high pressure lab, touched the ...
... organisms, germ cells give rise to gametes and serve ... germ cell development is the decision to leave mitosis ... eggs and sperm. Germ cell development involves unique gene ... ensure success during fertilization and embryo development. Written ...
Cached Biology News:Worm-tracking challenge leads to new tool for brain research 2Worm-tracking challenge leads to new tool for brain research 3Carnegie partners with USA Science & Engineering Festival for second year 2Carnegie partners with USA Science & Engineering Festival for second year 3
albumin from bovine serum (BSA), BODIPY® FL conjugate...
Full service including gene cloning, protien expression and purification of 1 liter culture....
albumin from bovine serum (BSA), fluorescein conjugate...
GOAT ANTI HUMAN PARAINFLUENZA VIRUS 2+3...
Biology Products: